A NIH study shows a daily antioxidant supplement slows late-stage dry age-related macular degeneration (AMD) progression by 55%.

The supplement contains vitamins C, E, beta-carotene, zinc, copper, lutein, and zeaxanthin.

It reduces the expansion of geographic atrophy regions in the retina towards the central foveal region.

Limited benefit observed for those with geographic atrophy in their central vision, significant benefit for others.

This slowing is crucial for maintaining capabilities like reading and driving.

The study analyzed data from the AREDS and AREDS2 trials.

Further clinical trials are planned to confirm these results.